Skip to main content
OpenTrials
Completed

NCT Number: NCT04723290

COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020

The management of the Grand Hôpital de Charleroi hospital authorized the performance of a serology for each member of the establishment's staff in order to better characterize the proportion of its employees who have already been in contact with the SARS CoV-2 virus for organizational and evaluation purposes symptoms.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Grand Hôpital de Charleroi

Charleroi, Hainaut, 6060, Belgium

About this study

At the start of the SARS-CoV-2 pandemic, several workers had symptoms compatible with COVID-19 at a time when PCR (smear) testing was only allowed for hospitalized people. In addition, the PCR test has a fairly low sensitivity. In this context, serology can make it possible to determine whether the symptoms are indeed linked to exposure to SARS-CoV-2.

As a hospital, and in order to prepare for a possible second epidemic wave, it is also useful to know the proportion of staff members who have already been in contact with the virus for organizational purposes and symptom assessment.

.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be a member of the staff of the Grand Hôpital de Charleroi who wishes to participate in order to know their immunity related to SARS CoV-2 after the first wave of pandemic.

Exclusion criteria

  • Not be part of the staff of the Grand Hôpital de Charleroi.

Treatment and study plan

Serological tests for SARS Cov-2

Diagnostic Test

Each participant will have a blood test on a dry tube of maximum 8 ml of whole blood

Primary outcomes

  1. Serological tests to know the level of antibodies against SARS CoV-2

    Time frame: up to 6 weeks

    The hospital has organized several schedules and appointments for each staff member depending on the ability to analyze laboratory samples and blood draws.

Sponsors and collaborators

Lead sponsor

Grand Hôpital de Charleroi

Other

Registry information

Official study title

SARS-CoV-2 Seroconversion Study Among GHdC Staff Members

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jan 25, 2021
Registry last updated
Mar 25, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.